Compare · ORKA vs QDEL
ORKA vs QDEL
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL carries a market cap of $4.24B.
- Over the past year, ORKA is up 568.3% and QDEL is down 60.0% - ORKA leads by 628.3 points.
- QDEL has been more active in the news (9 items in the past 4 weeks vs 5 for ORKA).
- QDEL has more recent analyst coverage (18 ratings vs 11 for ORKA).
- Company
- Oruka Therapeutics Inc.
- QuidelOrtho Corporation
- Price
- $68.97+2.03%
- $11.60+3.25%
- Market cap
- -
- $4.24B
- 1M return
- +57.38%
- -27.67%
- 1Y return
- +568.31%
- -60.03%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 9
- Recent ratings
- 11
- 18
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest ORKA
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)
Latest QDEL
- Chief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes
- Understanding and Addressing Syphilis Trends - and What's Being Missed
- SEC Form 4 filed by Sisitsky Nathaniel
- TTP Group Announces the Sale of LEX Diagnostics
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- SEC Form 3 filed by new insider Sisitsky Nathaniel